Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement - HIV/AIDS and/or STBBI

University of Calgary

$45,000.00

Proteases from vaginal Prevotella species as key drivers of endocervical susceptibility to HIV infection

EF 2023-24

Résumé
The vaginal microbiome is typically dominated by simple community of bacteria that play an important role in preventing infections. However, up to 30% of women have a condition known as bacterial vaginosis (BV), where the vaginal microbiome is imbalanced. Women with BV are 2-3X more susceptible to sexually transmitted infections such as HIV and chlamydia. The presence of specific BV bacteria further augments this susceptibility, increasing HIV risk by up to 13-fold. However, we do not understand how these bacteria modify the cervical environment to create a permissive environment for genital infections like HIV. During BV, there are decreased levels of immune factors that inactivate sexually transmitted pathogens like HIV. Additionally, there is a significant disruption to the cervical tissue integrity, which is important physical barriers that prevents HIV infection. Our data demonstrate that BV bacteria secrete proteolytic enzymes that degrade key structural proteins found in human cervical tissues. I will investigate whether these BV bacteria and their secreted enzymes can weaken cervical tissue and inactivate important immune factors to increase the invasion and infection by HIV. These investigations will improve our understanding of how the vaginal microbiome and BV increase the risk for sexually transmitted infections. By designing drugs that specifically inhibit BV-associated vaginal bacteria and their proteolytic enzymes, we could develop novel therapies that prevent sexually transmitted infections like HIV and chlamydia in vulnerable female populations.
Programme
Fellowship - Priority Announcement - HIV/AIDS and/or STBBI
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
497731
Name
Lithgow Karen V
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Proteases from vaginal Prevotella species as key drivers of endocervical susceptibility to HIV infection
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - HIV/AIDS and/or STBBI
Keyworddelim
Bacterial Vaginosis; Hiv; Human Cell Culture; Protease Activity; Proteomics; Sexually Transmitted Infections; Vaginal Microbiome
Abstract
The vaginal microbiome is typically dominated by simple community of bacteria that play an important role in preventing infections. However, up to 30% of women have a condition known as bacterial vaginosis (BV), where the vaginal microbiome is imbalanced. Women with BV are 2-3X more susceptible to sexually transmitted infections such as HIV and chlamydia. The presence of specific BV bacteria further augments this susceptibility, increasing HIV risk by up to 13-fold. However, we do not understand how these bacteria modify the cervical environment to create a permissive environment for genital infections like HIV. During BV, there are decreased levels of immune factors that inactivate sexually transmitted pathogens like HIV. Additionally, there is a significant disruption to the cervical tissue integrity, which is important physical barriers that prevents HIV infection. Our data demonstrate that BV bacteria secrete proteolytic enzymes that degrade key structural proteins found in human cervical tissues. I will investigate whether these BV bacteria and their secreted enzymes can weaken cervical tissue and inactivate important immune factors to increase the invasion and infection by HIV. These investigations will improve our understanding of how the vaginal microbiome and BV increase the risk for sexually transmitted infections. By designing drugs that specifically inhibit BV-associated vaginal bacteria and their proteolytic enzymes, we could develop novel therapies that prevent sexually transmitted infections like HIV and chlamydia in vulnerable female populations.
Competitiondate
202310
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lithgow, Karen V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $45,000~ $0~